Authors: Vanna Hovanky, Keyur Mehta
Institution: University of Texas at Austin
Cancer is one of the leading causes of death and affects over seven million people each year (American Cancer Society, 2011). Carbonic anhydrase IX (CAIX) is an enzyme that increases the survival of cancer cells and renders treatments ineffective by regulating tumor pH. The purpose of the project was to discover and test novel inhibitors of CAIX that can potentially block tumor growth. A total of 86,228 compounds were virtually screened. The DNA sequence coding for the human carbonic anhydrase IX protein was inserted into a bacte- rial expression vector and expressed and purified via nickel affinity tag. Spectrophotometric enzyme assays measured the effectiveness of the compounds in vitro. Virtual screening results demonstrated that metoprolol, pentamidine isethionate, and Chembridge compounds #7653639 and #7633756 have predicted drug-likeness and binding strength to the CAIX active site through favorable interactions of Van der Waals forces and hydrogen bonds. In the enzyme assays, the mean velocities decreased as the tested concentrations of the compounds increased from 0.5 μM to 100 μM. Overall, the selected compounds showed promise. Successful inhibition of CAIX in vitro affirms the importance of virtual screening and may contribute to the discovery of novel therapeutic cancer agents.
About 85% of all cancers are carcinomas, which are tumors of the epithelial tissue (Woolf, 2011), including some of the most common and the most fatal types of cancer. Carbonic anhydrase IX (CAIX, PDB ID: 3IAI) is an enzyme expressed in carcinomas (Alterio, 2009). It is part of the carbonic anhydrase (CA) family. These enzymes catalyze the reversible reaction in which a pro- ton and bicarbonate are produced from carbon dioxide and water. Unlike other enzymes of the CA family, CAIX is expressed in many forms of cancer, but not in most normal tissues. CAIX is cell density-dependent and has shown to be activated in tumors under stressful conditions including hypoxia, the latter implying deprivation of adequate oxygen supply from tissues (Robertson, 2004). In addition, CAIX activity is associated with cellular reproduction and transformation, increased rates of metastasis, and poor prog- nosis in aggressive carcinomas (Chia, 2001).
Virtual screening was used in order to identify potential CAIX inhibitors; virtual screening is the process of utilizing molecular docking software to analyze biological structures in order to discover novel drugs (Soichet, 2004). In order to bring a new drug to the market, up to $800 million and over 10 years of research can be spent (Geldenhuys, 2006). Although only recently developed, virtual screening can accelerate the introduction of new drugs to market while reducing the cost of development by up to 50% (Geldenhuys, 2006). GOLD, the docking program used in the study, scans numerous conformations of compounds in a library. The program returns a score that accounts for factors of binding affinity, which in turn may indicate inhibition in an enzyme-ligand complex. Factors include the number of hydrogen bonds and the extent of van der Waals forces (Cummings, 2005).
It is hypothesized in this study that virtual screening methods along with standard molecular biology techniques will yield specific inhibitors of CAIX that may improve cancer therapy. The four main objectives of this project were 1) to predict potential CAIX inhibitors by virtually screening many different compounds, 2) to clone the CAIX gene into an expression vector with ligation independent cloning, 3) to express and purify the CAIX protein, and 4) to test the potency of discovered inhibitors through in vitro enzyme assays.
CAIX increases the survival of cancer cells by regulating tumor pH (Chiche, 2009). CAIX’s negative effects are multifold. The activation of CAIX in the first stages of hypoxia allows the tumor cells to survive in increasingly hypoxic conditions. CAIX lowers tumor extracellular pH by producing protons. For normal cells, acidification of the micro-environment can be lethal, stopping vital intracellular processes such as cellular respiration. The CAIX of tumor cells prevents cancer cell death by producing HCO3-, which alkalizes the intracellular pH. Therefore, CAIX gives tumor cells an advantage in survival against normal cells (Figure 1). The extracellular acidification leads to chemo-resistance with slightly basic anti-cancer drugs (Švastová, 2004). In addition, radiation treatment is rendered less effective due to the lack of oxygen because free radicals that cause cellular tumor damage cannot be produced (Chia, 2009). Therefore, tumor cells aided by CAIX have further resistance to radiation treatment. Overall, the negative attributes of CAIX’s functionality in cancer make CAIX an attractive target for inhibition.
MATERIALS AND METHODS
Ligation independent cloning was used to insert the CAIX coding DNA sequence (Figure 2) into the pNIC28-Bsa4 expression vector designed by Gileadi et al. (2010) and obtained from the Arizona State University Plasmid Repository (Figure 2). Primers were de- signed to exclude parts of the CA9 sequence in polymerase chain reaction (PCR) that code for large hydrophobic regions. Hydrophobic residues cause difficulties in protein purification because of their low solubility and tendency to cause protein aggregation (Condron et al., 2008). The complete truncated amino acid sequence is the same as that on PDB used by Alterio et al (2009). PCR conditions followed EMD Millipore’s standard Thermococcus kodakaraensis polymerase (KOD1), according to the manufacturer’s instructions, with the exception of a 10 second annealing step at 59.6°C rather than at 55°C (EMD Milipore, 2013).
Gel electrophoresis and extraction were used in order to iso- late the desired PCR products to be inserted into the expression plasmid. The PCR samples were electrophoresed through 0.9% agarose gels containing ethidium bromide in 1xTAE buffer. Gels were viewed using a UV trans-illuminator. The bands of 771 base pairs (size of PCR insert) were manually cut out. A Gel Extraction kit (Sigma-Aldrich; St. Louis, MO) and a PCR Clean Up kit (Sigma-Aldrich; St. Louis, MO) purified samples using included chemicals and micro-centrifuge columns.
Eco311 restriction enzymes aligned the pNIC28-Bsa4 plasmid. T4 DNA polymerase created complimentary ends on the PCR insert and the linearized pNIC-Bsa4. Once the insert and vector annealed, the hybrid plasmid was transformed into NEB5α E. coli cells (New England Biolabs; Ipswich, MA), which were then plated on a lysogeny broth (LB) agar with kanamycin anti- biotic. Plasmids were isolated from E. coli using a Miniprep Kit (Qiagen; Valencia, CA). Plasmids with sequencing primers were sent to the University of Texas (UT) at Austin’s Core Facilities and sequenced with the UT Core’s standard Sanger DNA sequencing service.
Protein expression and purification
Positive clones were transformed into BL21 (DE3) competent cells. Colonies were inoculated into LB media overnight. After 16 hours, culture samples were adjusted to have a final OD600 (optical density at 600 nm wavelength) of 0.1. Isopropyl β-D-1- thiogalactopyranoside (IPTG) was added to a final concentration of 500 μM in order to induce CAIX expression. The expression took place overnight at room temperature (~20°C) rather than the standard 4 hours at 37°C. Cells were harvested by centrifuge and lysed by sonicator. Clarified liquid supernatant contained the CAIX protein ready for purification.
Ni-NTA agarose (Qiagen; Valencia, CA) was used to purify CAIX using a standard protocol for 6xHis-tagged proteins from E. coli (Qiagen, 2013). Fast protein liquid chromatography (FPLC) on a Superdex G75 column (General Electric Healthcare; Pittsburg, PA) purified the sample even further. CAIX protein concentrated using a Vivaspin concentrator (General Electric Healthcare; Pittsburg, PA) was stored in 20% glycerol at -20°C. Sodium do-decyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) was performed under a standard protocol (Caprette, 2012) for confirming the presence of the protein.
The carbonic anhydrase IX protein structure was obtained from the literature (Alterio, 2009) and viewed on the PyMol program (Schrödinger; Portland, OR). The protein was prepared for docking using the GOLD program (Jones et al., 1995). The active site cavity was measured as 7.5 angstroms around its central point. Two thousand eight hundred and nineteen hydrogen atoms were added. Four hundred and thirty excess water atoms and three excess ligands were deleted. This was done to optimize the virtual screening process. A script file was made for each run to distribute the docking jobs on multiple processors using the Sun Grid Engine (SGE). The job was run using an edited script command through the secure shell to the remote UT TI-3D computer cluster. In total, 85000 compounds from seven libraries were screened (Table 1).
The top 1% of the total library size was saved as high scoring ligands after several rounds of screening. These compounds were analyzed further with Pymoland Lipinski’s Rule of 5 (Lipinski, 2004). Lipinski’s Rule of 5 is composed of four criteria related to drug absorption, distribution, metabolic effect, and excretion in the human body (Lipinski, 2004). Compounds selected in the final list of top 10 potential CAIX inhibitors (Table 2) for further analysis and testing had the highest binding scores, the strongest predicted interactions in the CAIX active site, and at least three out of the four requirements in Lipinski’s Rules of 5 passed. Then the top four compounds to be analyzed in the enzyme assays were chosen on the criteria of both binding scores directly reported by GOLD program and statistical analysis.
In order to determine the potency of the chosen compounds in vitro, spectrophotometric enzyme assays were carried out using 4-nitrophenyl acetate (PNPA) as the substrate.
PNPA (Sigma-Aldrich; St. Louis, MO) was used because of its structural similarity to HCO3-. In our study, the surrogate is the reactant although this reverse reaction catalyzed by CAIX does not take place in the human body in appreciable amounts because it is not nearly as abundant in a cell as CO2. However, it is difficult to quantify the CO2, H2O, H+, and HCO3- of the natural reaction. P-nitrophenol (PNP) and acetic acid are the products of the reaction when PNPA is the reactant. P-nitrophenol has an OD that is easily read by a spectrophotometer at 400 nm (Sies, 2005). Optical density at a 400 nm over time, or mean velocity, shows the rate at which CAIX catalyzes the reaction and makes PNP. Thus, a smaller mean velocity indicates an inhibited enzyme because less PNP is being made.
Assay buffer with a pH of 7.5 consisted of 25 mM tris and 150 mM NaCl. Compounds were diluted in dimethyl sulfoxide (DMSO) (Sigma-Aldrich; St. Louis, MO). Wells in the 96-well plates had 100 ng of enzyme in buffer, water, a final concentration of 1mM 4-nitrophenyl acetate (PNPA) and the chosen compound and concentration to be tested. The Biotek Synergy HT Microplate Reader (BioTek; Winooski, VT) measured OD of each sample every 33 seconds for a total of 20 minutes.
Agarose gel electrophoresis showed successful PCR amplification of the 771 base pair CA9 gene. Cutting of pNIC-Bsa4 by Eco3111 restriction enzyme was also confirmed (Figure 3). This demonstrates that the expression vector was successfully linearized which is necessary for subsequent cloning processes. The Basic Local Alignment Search Tool (Altschul, 1990) comparison between the target sequence and the sequence of the sample showed the CAIX coding DNA sequence was correctly inserted into pNIC-Bsa4 expression vector (Figure 3). This cloned hybrid CAIX-expression plasmid allows for CAIX protein expression. After expression and purification, SDS-PAGE showed a protein band of approximately 28 kilodaltons. Because the CAIX protein has a size of 28 kilodaltons, it is concluded that the protein present in the sample is CAIX.
A box plot (Figure 4) compared the binding scores of the top compounds to those of other compounds. Chembridge #7653639, Chembridge #7633756, metoprolol, and pentamidine isethionate all had high binding scores and z-scores, which reflect the differences in binding scores of chosen compounds to those of other compounds in the same library. The binding scores ranged from 84.51 to 91.78 and result from similarly high Van der Waals and hydrogen bond sub-scores. All four passed the Lipinski’s Rule of 5 Test for drug-likeness and were used in the enzyme assays.
As the concentration of the compounds increased from 0.5 μM to 100 μM, the average mean velocities decreased. The average mean velocity of the enzyme without any inhibitors was 2.184 mOD/min. At 100 μM, the top two inhibitors, Chembridge compound #7653639 and #7633756, had an average mean velocity of 1.519 mOD/min and 1.565 mOD/min, respectively (Figures 5, 6). The lower mean velocities indicate that the reaction catalyzed by CAIX progresses at a slower rate. Thus, the compounds can be concluded to result in CAIX’s inhibition.
Two-sample t-tests with an alpha level of 0.05 were used to determine if the mean velocities of control wells were significantly different from experimental wells (Table 3). Fifteen out of 16 sample comparison (control vs. 0.5 μM concentration of metoprolol) returned p-values below the alpha level. This shows that the mean velocities of the control sample were significantly higher than those of the samples containing the compounds and are not likely due to random error.
Discussion and Conclusions
The hypothesis was supported by this study; specific inhibitors of CAIX, which may improve cancer therapy, were discovered by the successful completion of the 4 research objectives. The research objectives included the cloning of the CAIX gene, the expression and purification of the CAIX protein, the virtual screening of CAIX’s X-ray crystallography structure, and finally, the testing of four chemical inhibitors to CAIX. The standard molecular biology methods used in this study, along with the less common methods such as ligation independent cloning rather than T/A cloning and overnight protein expression rather than four-hour expression, were shown to be effective in obtaining sufficient amounts of CAIX protein for use in enzyme assays. As compared to traditional methods, virtual screening yielded results of predicted inhibitors in a manner saving both time and resources.
All four compounds show evidence of inhibiting the CAIX protein when tested in vitro. The top two inhibiting compounds in the enzyme assay were Chembridge compound #7653639 and #7633756. The higher effectiveness of the two Chembridge compounds in enzyme inhibition would result from the greater affinity of these two compounds have to the CAIX active site. Chembridge #7653639 and #7633756 have molecular weights of 409 and 466, respectively (Chembridge, 2010). On the other hand, metoprolol and pentamidine isethionate have molecular weights of 685 and 593, respectively (Sigma-Aldrich, 2013). The results showing decreased effectiveness of the metoprolol and pentamidine isethionate as inhibitors may thus indicate a disadvantage in using larger compounds because they do not fit as well in the CAIX active site. The decreased inhibition may also be caused by a number of other factors such as greater number of hydrogen bonds or Van der Waals forces. Greater understanding of the causes for the com- pounds’ effectiveness may be further elucidated with additional tests such as x-ray crystallography.
Although metoprolol and pentamidine isethionate have lower inhibition results, they offer a great case for drug repurposing be- cause they are already on the market for different diseases. Pentamidine isethionate is currently used as an anti-infective agent (Western, 1970) and was tested in rats to see its effect on anti-tumor necrosis factors (Chen et al., 1994). CAIX inhibition by pentamidine isethionate may be very promising because it could target cancer in two separate ways. Metoprolol is commonly used drug for hypertension and heart disease (Benfield, 1986). Because these compounds already passed clinical trials, the road to becoming an official, generally used drug for cancer may be significantly shortened.
Inhibitors of carbonic anhydrase (CA) have previously been found in other studies. However, these drugs target the CA family as a whole instead of CAIX specifically. Many members of the family actually have beneficial effects for humans; thus, these known inhibitors have high toxicity and a number of side effects (Supuran, 2010). This research presented here is novel in that it concerns the inhibition of specifically CAIX, a protein that is only activated in cancer cells. Future studies with the four compounds would need to be carried out to determine their effect upon the CA family as a whole to further determine specificity.
While a variety of research has been done on CA using high- throughput screening and other trial and error based methods (Miyazaki, 2008), studies analyzing inhibitors via virtual drug screening are limited. Traditional virtual drug screening is measured entirely by binding score (Soichet, 2004). This research chose to use a statistical process less commonly used (Sastry, 2013) to measure inhibition potential. A ligand’s z-score within its own library was added to the screening process so that the integrity of the ligand was not solely based on a single binding score. By scoring significantly above other compounds, a ligand shows greater inhibition potential. Using z-scores helped the researchers to find ligands, such as the chosen Chembridge compounds, with low relative binding scores but with significant drug potential.
Additional studies will further enhance our understanding of the compounds’ potential. A larger number of trials may be conducted to decrease the likelihood of random errors, which may arise from spectrophotometer error or sample composition variation from potentially insufficient mixing. Virtual screening may be done on more compound libraries to find additional potential inhibitors of CAIX. Also, the remaining compounds in Table 2 may be tested using enzyme assays. CAIX, and its prospective inhibitors may be tested in cell-based assays using animal and human cancer cells in a hypoxic environment. If further studies are successful, CAIX inhibitors in this study have the potential to drastically improve both the treatment and the prognosis of cancer patients all over the world.
This research was supported by the Virtual Drug Screening Stream/Freshman Research Initiative program (College of Natural Sciences) at the University of Texas at Austin. Thank you to Dr. Josh Beckham for providing guidance regarding the study’s design and procedures.
Alterio, V., Hilvo, M., Difiore, A., Supuran, C., Pan, P., Parkkila, S., Scaloni, A., Pastorek, J., Pastoreková, S., Monti, S. M., & De Simone, G. (2009). Crystal structure of the catalytic domain of the tumor-associated human carbonic anhydrase IX. Proceedings of the Natural Academy of Sciences of the United States of America, 106(38), 16233-16238.
Altschul, S. F., Gish, W., Miller, W., Myers, E. W., & Lipman, D.J. (1990). Basic local alignment search tool. J. Mol. Biol. 215: 403-410.
American Cancer Society. (2011). Global Cancer Facts & Figures 2nd Edition. Atlanta: American Cancer Society.
Benfield, P., Clissold, S., & Brogden, R. (1986). Metoprolol. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in hypertension, ischaemic heart disease and related cardiovascular disorders.Drugs. 31(5), 376-429.
CA9 carbonic anhydrase IX [Homo sapiens] - Gene - NCBI.(n.d.). National Center for Biotechnology Information. Retrieved from http://www.ncbi.nlm.nih.gov/gene/768.
Caprette, D. (2012). SDS-PAGE. Retrieved from http://www.ruf.rice.edu/~bioslabs/studies/sds-page/gellab2.html
Chen, Y., Vraux, V. L., Giroud, J., & Chauvelot-Moachon, L. (1994). Anti-tumor necrosis factor properties of non-peptide drugs in acute-phase responses. European Journal of Pharmacology, 271(2-3), 319-327.
Chia, S., Wykoff, C., Watson, P., Han, C., Leek, R., Pastorek, J., Gatter, K. C., Ratcliffe, P., & Harris, A. L. (2001). Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma. Journal of Clinical Oncology, 19(16), 3660-3668.
Chiche, J., Ilc, K., Laferrier, J., Trottier, E., Dayan, F., Mazure, N., Brahimi-Horn, M. C., & Pouysségur, J. (2009). Hypoxia-inducible carbonic anhydrase IX and XII promote tumor cell growth by counteracting acidosis through the regulation of the intracellular pH .Cancer Research, 69(1), 358-363.
Condron, M. M., Monien, B. H., & Bitan, G. (2008). Synthesis and purification of highly hydrophobic peptides derived from the c-terminus of amyloid β-protein. The Open Biotechnology Journal, 2(1), 87-93.
Cummings, M., DesJarlais, R., Gibbs, A., Mohan, V., & Jaegar, E. (2005). Comparison of automated docking programs as virtual screening tools. Journal of Medicinal Chemistry, 48(4), 962-976.
DeLano, W. L. (2002). The PyMOL molecular graphics system (Version 184.108.40.206) [computer program]. Schrödinger, LLC. Available from http://www.pymol.org/.
EMD Millipore. (n.d.) KOD Hot Start DNA Polymerase. Accessed via http://www.emdmillipore.com/life-science-research/kodhot/c_LICb.s1OjIcAAAEhg7ksgjFC.
Geldenhuys, W. (2006). Optimizing the use of open-source software applications in drug discovery. Elsevier, 11(6), 127-132.
Jones, G., Willett, P., & Glen, R. (1995). GOLD [computer software]. Available from http://www.ccdc.cam.ac.uk/Solutions/GoldSuite/Pages/GOLD.aspx
Lipinski, C. (2004). Lead- and drug-like compounds: The rule-of-five revolution. Drug Discovery Today: Technologies,1(4), 337-341.
Park, H., Kim, Y., & Hahn, J. (2007). A novel class of Hsp90 inhibitors isolated by structure-based virtual screening. Bioorganic & Medicinal Chemistry Letters, 17(22), 6345-6349.
Qiagen. Ni-NTA Agarose. (n.d.). Retrieved from http://www.qiagen.com/products/catalog/sample-technologies/protein-sample-technologies/purification-kits-and-resins/ni-nta-agarose#resources.
Reynolds, J. & Aiseman, E. (1992). Pentamidine is an N-methyl-D-aspartate receptor antagonist and is neuroprotective in vitro. The Journal of Neuroscience, 12(3), 970-975.
Robertson, N. (2004). Role of carbonic anhydrase IX in human tumor cell growth, survival, and invasion. Cancer Research, 64(17), 6160-6165.
Sastry, G. (2013). Boosting virtual screening enrichments with data fusion: Coalescing hits from two-dimensional fingerprints, shape, and docking.Journal of chemical information and modeling, 53(7), 1531-42.
Sies, H., & Packer, L. (Eds.). (2005). Phase II conjunction enzymes and transport systems. Methods in enzymology. San Diego, CA: Elsevier Academic Press.
Soichet, B. (2004). Virtual screening of chemical libraries. National Institute of Health, 432(7019), 862-865.
Supuran, C. T. (2010). Carbonic anhydrase inhibitors. Bioorganic & Medicinal Chemistry Letters, 20(12), 3467-3474.
Švastová, E., Hulı́ková, A., Rafajová, M., Gibadulinová, A., Casini, A., Cecchi, A., Scozzafava, A., Supuran, C. T., Pastorek, J., & Pastoreková, S. (2004). Hypoxia activates the capacity of tumor-associated carbonic anhydrase IX to acidify extracellular pH. Federation of European Biochemical Societies Letters, 577(3), 439–445.
Western, K., & Perera, D. (1970). Pentamidine isethionate in the treatment of pneumocystis carinii pneumonia. Annals of Internal Medicine, 73(5), 695-702.